Positively Inclined for Potential Approval of Aeglea's (AGLE) pegzilarginase BLA - Needham & Company
Tweet Send to a Friend
Needham & Company analyst Gil Blum reiterated a Buy rating and $12.00 price target on Aeglea Biotherapeutics (NASDAQ: AGLE), following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
